IN2014DN05784A - - Google Patents

Download PDF

Info

Publication number
IN2014DN05784A
IN2014DN05784A IN5784DEN2014A IN2014DN05784A IN 2014DN05784 A IN2014DN05784 A IN 2014DN05784A IN 5784DEN2014 A IN5784DEN2014 A IN 5784DEN2014A IN 2014DN05784 A IN2014DN05784 A IN 2014DN05784A
Authority
IN
India
Prior art keywords
prophylaxis
analogue
peptide
treatment
condition
Prior art date
Application number
Other languages
English (en)
Inventor
George Edward Rainger
Parth Narendran
Helen Mcgettrick
Myriam Chimen
Original Assignee
Univ Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Birmingham filed Critical Univ Birmingham
Publication of IN2014DN05784A publication Critical patent/IN2014DN05784A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
IN5784DEN2014 2012-01-13 2013-01-14 IN2014DN05784A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201200555A GB201200555D0 (en) 2012-01-13 2012-01-13 Peptide
PCT/GB2013/050068 WO2013104928A1 (en) 2012-01-13 2013-01-14 Peptide and uses thereof

Publications (1)

Publication Number Publication Date
IN2014DN05784A true IN2014DN05784A (enExample) 2015-05-15

Family

ID=45813974

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5784DEN2014 IN2014DN05784A (enExample) 2012-01-13 2013-01-14

Country Status (7)

Country Link
US (1) US9597368B2 (enExample)
EP (1) EP2802342B1 (enExample)
JP (1) JP6055845B2 (enExample)
CN (1) CN104168910B (enExample)
GB (1) GB201200555D0 (enExample)
IN (1) IN2014DN05784A (enExample)
WO (1) WO2013104928A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165218A1 (en) * 2017-03-09 2018-09-13 Allysta Pharmaceuticals, Inc Peptides for dry eye disease
WO2020102623A1 (en) * 2018-11-15 2020-05-22 The University Of Toledo Materials and methods for the prevention of rheumatoid arthritis
US20210100870A1 (en) * 2019-10-08 2021-04-08 The University Of Birmingham Bone disease treatment
GB202211043D0 (en) 2022-07-28 2022-09-14 Univ Birmingham Peptide agonist
CN117244043B (zh) * 2023-11-02 2024-09-20 徐州医科大学附属医院 破伤风类毒素在治疗血管内皮细胞损伤中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216273A1 (en) 2000-12-29 2002-07-16 Oxford Glycosciences (Uk) Limited Proteins, genes and their use for diagnosis and treatment of kidney response
CA2679301C (en) 2007-02-28 2015-08-11 University Of Virginia Patent Foundation Lisofylline analogs and methods for use in protecting pancreatic .beta.-cells, treating type 1 diabetes, and treating inflammatory and autoimmune diseases
BRPI0819063A2 (pt) * 2007-11-27 2020-08-18 The University Of British Columbia método para tratamento de artrite, anticorpo, hibridoma, antagonista de 14-3-3, usos de um antagonista de 14-3-3, composições farmacêuticas, método para redução da expressão de mmp no sinóvio de um paciente e usos de uma composição farmacêutica
EP2679238A1 (en) * 2008-10-02 2014-01-01 Celtaxsys, INC. Methods of modulating the negative chemotaxis of immune cells
US20110130415A1 (en) * 2009-12-01 2011-06-02 Rajinder Singh Protein kinase c inhibitors and uses thereof
WO2011154496A1 (en) * 2010-06-09 2011-12-15 Poxel Treatment of type 1 diabetes

Also Published As

Publication number Publication date
US9597368B2 (en) 2017-03-21
EP2802342A1 (en) 2014-11-19
EP2802342B1 (en) 2018-05-02
JP2015509095A (ja) 2015-03-26
WO2013104928A1 (en) 2013-07-18
CN104168910B (zh) 2017-07-28
JP6055845B2 (ja) 2016-12-27
US20150051137A1 (en) 2015-02-19
GB201200555D0 (en) 2012-02-29
CN104168910A (zh) 2014-11-26

Similar Documents

Publication Publication Date Title
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
EA202091639A3 (ru) Лечение панкреатита
IN2014KN02830A (enExample)
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MY184241A (en) Human antibodies to gfr?3 and methods of use thereof
WO2012093258A3 (en) Irf5- related treatment and screening
SG10201809701TA (en) Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent
PH12016501051A1 (en) Methods of treasting and preventing alloantibody driven chronic graft versus host disease
MX2012009718A (es) Material biodegradable que contiene silicio para terapia antiinflamatoria.
EA201500061A1 (ru) Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением
TW201613592A (en) Glucose metabolism ameliorating agent
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
MX2013007995A (es) Peptidos derivados de lactoferrina humana y su uso.
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2015012580A (es) El uso de sdf-1 para atenuar la formacion de cicatrices.
WO2014142760A3 (en) Re-trafficking of herg reverses long qt syndrome 2 phenotype in human ips-derived cardiomyocytes
EP4219534A3 (en) Methods for treatment of and prophylaxis against inflammatory disorders
TN2015000315A1 (en) Methods of treating cardiovascular indications
CO7151515A2 (es) Métodos para tratar deficiencia en la marcha y/o equilibrio en pacientes con esclerosis múltiple que utilizan una aminopiridina
WO2014144731A3 (en) Compositions comprising hypoxia inducible factor-1 alpha and methods of using the same
SG10201809280PA (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
WO2014122638A3 (en) Thalidomide and thalidomide analogues for the stimulation of stem cell factor
EA201591856A1 (ru) Лечение сердечной недостаточности
NZ705229A (en) Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity
MX2020007183A (es) Inhibidores de ret9 y vegfr2.